Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 520.48B | 398.83B | 314.56B | 555.54B | 560.03B | 515.95B |
Gross Profit | 379.35B | 245.40B | 187.98B | 376.63B | 402.91B | 378.18B |
EBITDA | 109.76B | 57.58B | -281.07B | -3.50B | 124.36B | 103.11B |
Net Income | 67.03B | 23.63B | -314.97B | -74.51B | 56.41B | 56.22B |
Balance Sheet | ||||||
Total Assets | 742.60B | 742.60B | 907.51B | 1.13T | 1.31T | 1.31T |
Cash, Cash Equivalents and Short-Term Investments | 23.12B | 23.12B | 29.05B | 163.65B | 238.58B | 223.18B |
Total Debt | 305.42B | 305.42B | 418.88B | 334.72B | 269.05B | 273.82B |
Total Liabilities | 573.13B | 573.13B | 751.37B | 727.96B | 634.44B | 659.95B |
Stockholders Equity | 169.48B | 169.48B | 156.06B | 406.75B | 607.89B | 580.57B |
Cash Flow | ||||||
Free Cash Flow | 105.33B | 8.00B | -257.62B | -805.00M | 17.75B | 124.80B |
Operating Cash Flow | 117.23B | 16.50B | -241.89B | 11.94B | 31.24B | 135.60B |
Investing Cash Flow | 7.59B | 99.75B | 33.04B | 52.42B | -18.28B | 8.88B |
Financing Cash Flow | -27.81B | -108.84B | 77.85B | -146.82B | -21.43B | -57.22B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $2.20T | 12.51 | 12.99% | 2.31% | 0.73% | 7.75% | |
75 Outperform | ¥211.02B | 6.48 | 3.96% | 8.08% | 25.92% | ||
73 Outperform | ¥292.00B | 13.54 | 7.90% | 2.15% | 10.09% | 63.28% | |
72 Outperform | $1.16T | 25.22 | 5.34% | 3.87% | 6.42% | 10.82% | |
65 Neutral | ¥7.04T | 64.95 | 1.50% | 4.41% | 7.45% | -25.77% | |
62 Neutral | ¥355.58B | 15.05 | 13.50% | ― | 26.79% | ― | |
52 Neutral | $7.53B | 0.32 | -61.76% | 2.28% | 16.60% | 1.56% |
Sumitomo Pharma Co., Ltd. has announced the assignment of key product assets in the U.S. from its subsidiaries to itself, aiming to enhance its direct involvement in the U.S. market. This strategic move, valued at approximately USD 1.8 billion, is part of a broader capital reorganization to strengthen the company’s revenue stream and operational control in the U.S., reflecting the growing importance of this market for Sumitomo Pharma’s overall business strategy.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
Sumitomo Pharma Co., Ltd. announced details about its relationship with its parent company, Sumitomo Chemical Co., Ltd., which holds a 51.78% voting interest. The announcement highlights the company’s operational independence, despite its integration into the parent company’s corporate group. The collaboration includes joint ventures in regenerative medicine and shared resources, but the company maintains managerial independence, with no limitations imposed on its business activities by the parent company.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
Sumitomo Pharma Co., Ltd. has announced a strategic restructuring of its Asian business through a simplified absorption-type company split. This involves transferring 60% of shares of a newly established subsidiary to Marubeni Global Pharma Corporation, with the option to transfer the remaining 40% in the future. This move is expected to enhance Sumitomo Pharma’s operational focus and market positioning in Asia, potentially impacting stakeholders by aligning with Marubeni’s resources and market reach.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
Sumitomo Pharma has announced ‘Reboot 2027,’ a strategic plan for FY2025-FY2027, aiming to stabilize its revenue base and enhance its position as an R&D-driven pharmaceutical company. The plan includes financial targets such as expanding sales of key products and reducing debt, alongside initiatives to innovate in oncology and regenerative medicine. The company seeks to improve its value creation cycle and establish a distinctive global presence, with a focus on strategic growth and innovation.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
Sumitomo Pharma Co., Ltd. announced the transfer of its Asian business to a new subsidiary, with 60% of shares being acquired by Marubeni Global Pharma Corporation. This transaction is expected to generate a gain of approximately 45 billion yen, impacting the company’s financial forecast for the fiscal year ending March 2026.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
Sumitomo Pharma Co., Ltd. announced a proposal to amend its Articles of Incorporation to transition to a company with an Audit & Supervisory Committee, aiming to enhance corporate governance and decision-making processes. The amendments will include changes to the roles of directors and the establishment of new provisions to support strategic discussions and improve oversight.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
Sumitomo Pharma Co., Ltd. announced its plan to transition to a company with an Audit and Supervisory Committee, pending approval at the upcoming Annual Shareholders’ Meeting. The Board of Directors has appointed candidates for executive and key personnel roles, with several directors and committee members being confirmed, subject to shareholder approval. This transition is expected to enhance the company’s governance structure, potentially impacting its operational oversight and strategic direction.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
Sumitomo Pharma Co., Ltd. announced a reversal of allowance for doubtful accounts amounting to 46,556 million yen in its non-consolidated financial statements for the fiscal year ended March 31, 2025. This adjustment, recorded as extraordinary income, will not affect the company’s consolidated profit or loss as it will be eliminated in the consolidated financial statements.
Sumitomo Pharma has revised its financial forecasts for the fiscal year ending March 31, 2025, showing an increase in expected revenue and profits due to higher-than-anticipated sales in North America. Additionally, the company recorded significant gains from the transfer of equity interests in its regenerative medicine and cell therapy business, which positively impacts its financial results.